Glossary Term
Liquid Biopsy Diagnostics
Definition
Liquid biopsy diagnostics refer to non-invasive tests that analyze biological markers, such as circulating tumor DNA (ctDNA), RNA, proteins, or exosomes, in bodily fluids like blood, urine, or saliva. These diagnostics are used to detect, monitor, and manage diseases, particularly cancer, without the need for surgical tissue biopsies.
Relevance to the MedTech Industry
Liquid biopsy diagnostics represent a significant advancement in precision medicine by enabling early disease detection, real-time monitoring, and personalized treatment strategies. They reduce the need for invasive procedures and improve patient outcomes through rapid and accurate molecular insights.
Additional Information & Related Terms
Examples of Applications in MedTech
Cancer Screening: Detecting early-stage cancers by identifying ctDNA mutations in blood samples.
Therapy Monitoring: Tracking tumor response to treatments like immunotherapy or targeted therapies.
Minimal Residual Disease (MRD): Identifying microscopic traces of cancer that may lead to relapse after treatment.
Prenatal Testing: Non-invasive prenatal testing (NIPT) to screen for fetal genetic abnormalities.
Transplant Medicine: Monitoring for organ rejection through cell-free DNA analysis.
Related Terms
Circulating Tumor DNA (ctDNA): Fragments of DNA released into the bloodstream by tumor cells.
Exosomes: Extracellular vesicles that carry proteins, RNA, and DNA, used as biomarkers in liquid biopsies.
Next-Generation Sequencing (NGS): A high-throughput method used in liquid biopsy analysis to identify genetic mutations.
Biomarker: A biological molecule used as an indicator of normal or pathological processes or treatment responses.
Companion Diagnostics: Tests developed alongside therapies to determine their suitability for specific patients.